1. GDM treatment targets for glycaemic control from Clinical Practice Guidelines.
| Fasting plasma glucose mmol/L (mg/dL)1 |
1‐hour postprandial mmol/L (mg/dL)1 |
2‐hours postprandial mmol/L (mg/dL)1 |
|
| Australasian Diabetes in Pregnancy Society (ADIPS) Nankervis 2013 (p. 5) and New Zealand Ministry of Health (NZMOH) New Zealand Ministry of Health 2014 (p. 32) |
≤ 5.0 (90) | ≤ 7.4 (133) | ≤ 6.7 (120) |
| American Diabetes Association (ADA) ADA 2013 (S21) Canadian Diabetes Association (CDA) Thompson 2013 (S178) |
≤ 5.3 (95) | ≤ 7.8 (140) | ≤ 6.7 (120) |
| National Institute of Health and Clinical Excellence (NICE) NICE 2015 (p. 21) |
< 5.3 (95) | < 7.8 (140) | < 6.4 (115) |
| 5th International Workshop on GDM Metzger 2007 (S254) |
5.0 (90) to 5.5 (99) | < 7.8 (140) | < 6.7 (120) to 7.1 (127) |
| Scottish Intercollegiate Guidelines Network SIGN 2014 (p. 59) |
4.0 (72) to 6.0 (108) | < 8.0 (144) | < 7.0 (126) |
| German Diabetes Asociation (DDA) Kleinwechter 2014 (p. 404) |
3.6 (65) to 5.3 (95) | < 7.8 (140) | < 6.7 (120) |
1RM converted all published glycaemic values for GDM treatment into both mmol/L or mg/dL